Eli Lilly Shares Rise After Retatrutide Trial Results
Shares rose 1.21% to $1,297.37 at 11:24 a.m. ET after Reuters reported that experimental retatrutide beat Ozempic on weight loss and blood sugar control.
Eli Lilly NYSE:LLY has another weapon in the diabetes and obesity drug race. Shares rose 1.21% to $1,297.37 at 11:24 a.m. ET on October 28 as Reuters reported that its experimental retatrutide beat Ozempic on weight loss and blood sugar control. The comparison used Ozempic's highest approved diabet…